Multi-organism platform for functional analysis of Undiagnosed Diseases Network (UDN) variants
Multi-organism platform for functional analysis of Undiagnosed Diseases Network (UDN) variants
批准号:
10600552
负责人:
TIM SCHEDL
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-02 至 2023-06-30
关键词:
Animal ModelBioinformaticsBiological AssayBiological ModelsCRISPR/Cas technologyCaenorhabditis elegansClinicalCommunicationCommunitiesCost Effectiveness AnalysisDiagnosisDiagnosticDiseaseEnvironmentEvaluationGeneticGenetic ModelsHumanIndividualKnock-inLeadershipLiteratureMissionModelingOrganismOrthologous GeneParticipantPathogenicityPatientsPhasePhenotypeResearchResourcesSymptomsTechniquesUnited States National Institutes of HealthUniversitiesVariantWashingtonZebrafishbioinformatics networkclinical research sitecost effectiveexperienceexperimental analysisgain of functiongene networkgenetic analysisgenetic variantknock-downloss of functionmedical schoolsmodel organisms databasesnoveloverexpressionscreening
中文摘要
项目总结
英文摘要
Project Summary
This application proposes the Washington University in St. Louis School of Medicine (WUSM) Model Organism
Screening Core (wuMOSC) as a key asset for Phase II of the NIH Undiagnosed Diseases Network (UDN). The
wuMOSC will evaluate the pathogenicity of genetic variants identified by UDN Clinical Sites in otherwise
undiagnosed participants by leveraging the two well-established animal model organisms Resource Cores: C.
elegans and zebrafish. This approach capitalizes on the experimental advantages of these two model systems,
while avoiding the limitations of individual models. C. elegans allows for extremely rapid and cost-effective variant
evaluation, while zebrafish enables assessment of genes and variants that are not conserved in C. elegans. An
experienced Leadership Team has been assembled that harnesses the collaborative research environment at
WUSM, including the expertise of the superb WUSM clinical partners that constitute the proposed UDN Phase
II WUSM Clinical Site application. Using proven, cutting-edge, and novel bioinformatic approaches, combined
with thoughtful consideration of the advantages and limitations of each model organism, a careful assessment
plan has been defined for determining the putative pathogenicity of nominated variants and prioritizing them for
experimental evaluation by the Resource Cores. The Resource Cores are using efficient and advanced genetic
targeting techniques, including CRISPR/Cas9 to knock-in the human variant into an orthologous gene, knock-
down and loss-of-function assays where appropriate, and overexpression to assess rescue of loss-of-function
or for gain-of-function. Phenotypic analysis of the genetic models will be guided by information in model organism
databases and the literature, as well as patient symptoms. This information will then be applied to the organism-
specific phenotyping pipelines. The UDN Clinical Sites, Steering Committee, and Coordinating Committee will
receive frequent communications regarding plans and results of the wuMOSC, through the activity of the
Administrative Core, which will also disseminate acquired model organism expertise to the wider NIH and other
research communities. As demonstrated over the past four years, the wuMOSC will continue to advance the
diagnostic efforts of the UDN by bioinformatically and experimentally evaluating the potential of disease-causing
variants in the context of disease-specific phenotypes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-organism platform for functional analysis of Undiagnosed Diseases Network (UDN) variants
-
批准号:10213222
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2018
-
负责人:TIM SCHEDL
-
依托单位:
C. elegans Resource Core
-
批准号:10213225
-
项目类别:
-
资助金额:$11.01万
-
财政年份:2018
-
负责人:TIM SCHEDL
-
依托单位:
Leadership Implementation Project
-
批准号:10213226
-
项目类别:
-
资助金额:$5.77万
-
财政年份:2018
-
负责人:TIM SCHEDL
-
依托单位:
Streamlined capture and curation of unpublished data
-
批准号:9980493
-
项目类别:
-
资助金额:$55.84万
-
财政年份:2017
-
负责人:TIM SCHEDL
-
依托单位:
IDENTIFICATION OF ERK SUBSTRATES THAT DRIVE PROLIFERATION IN RAS TUMORS
-
批准号:8810230
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2014
-
负责人:TIM SCHEDL
-
依托单位:
IDENTIFICATION OF ERK SUBSTRATES THAT DRIVE PROLIFERATION IN RAS TUMORS
-
批准号:8690290
-
项目类别:
-
资助金额:$16.57万
-
财政年份:2014
-
负责人:TIM SCHEDL
-
依托单位:
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
-
批准号:8258381
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
-
批准号:8415952
-
项目类别:
-
资助金额:$27.87万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
Stem cell versus meiotic fate decision in C. elegans
-
批准号:10406345
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
-
批准号:9340215
-
项目类别:
-
资助金额:$37.52万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
-
批准号:9176052
-
项目类别:
-
资助金额:$37.52万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
-
批准号:8585862
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
Stem cell versus meiotic fate decision in C. elegans
-
批准号:10224219
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
Stem cell versus meiotic fate decision in C. elegans
-
批准号:10630932
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2012
-
负责人:TIM SCHEDL
-
依托单位:
MPK -1 ERK SUBSTRATES AND THE CONTROL OF GERMLINE DEVELOPMENT
-
批准号:7506027
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2008
-
负责人:TIM SCHEDL
-
依托单位:
MPK -1 ERK SUBSTRATES AND THE CONTROL OF GERMLINE DEVELOPMENT
-
批准号:7881391
-
项目类别:
-
资助金额:$33.11万
-
财政年份:2008
-
负责人:TIM SCHEDL
-
依托单位:
MPK -1 ERK SUBSTRATES AND THE CONTROL OF GERMLINE DEVELOPMENT
-
批准号:8102162
-
项目类别:
-
资助金额:$32.77万
-
财政年份:2008
-
负责人:TIM SCHEDL
-
依托单位:
MPK -1 ERK SUBSTRATES AND THE CONTROL OF GERMLINE DEVELOPMENT
-
批准号:7679608
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2008
-
负责人:TIM SCHEDL
-
依托单位:
ANALYSIS OF GERM LINE SEX DETERMINATION IN C ELEGANS
-
批准号:2199655
-
项目类别:
-
资助金额:$26.18万
-
财政年份:1989
-
负责人:TIM SCHEDL
-
依托单位:
ANALYSIS OF GERM LINE SEX DETERMINATION IN C ELEGANS
-
批准号:2199654
-
项目类别:
-
资助金额:$22.36万
-
财政年份:1989
-
负责人:TIM SCHEDL
-
依托单位:
海外基金